» Articles » PMID: 37887568

Application of Machine Learning in Predicting Hepatic Metastasis or Primary Site in Gastroenteropancreatic Neuroendocrine Tumors

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2023 Oct 27
PMID 37887568
Authors
Affiliations
Soon will be listed here.
Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) account for 80% of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). GEP-NETs are well-differentiated tumors, highly heterogeneous in biology and origin, and are often diagnosed at the metastatic stage. Diagnosis is commonly through clinical symptoms, histopathology, and PET-CT imaging, while molecular markers for metastasis and the primary site are unknown. Here, we report the identification of multi-gene signatures for hepatic metastasis and primary sites through analyses on RNA-SEQ datasets of pancreatic and small intestinal NETs tissue samples. Relevant gene features, identified from the normalized RNA-SEQ data using the mRMRe algorithm, were used to develop seven Machine Learning models (LDA, RF, CART, k-NN, SVM, XGBOOST, GBM). Two multi-gene random forest (RF) models classified primary and metastatic samples with 100% accuracy in training and test cohorts and >90% accuracy in an independent validation cohort. Similarly, three multi-gene RF models identified the pancreas or small intestine as the primary site with 100% accuracy in training and test cohorts, and >95% accuracy in an independent cohort. Multi-label models for concurrent prediction of hepatic metastasis and primary site returned >98.42% and >87.42% accuracies on training and test cohorts, respectively. A robust molecular signature to predict liver metastasis or the primary site for GEP-NETs is reported for the first time and could complement the clinical management of GEP-NETs.

Citing Articles

Estimating prognosis of gastric neuroendocrine neoplasms using machine learning: A step towards precision medicine.

Wang H, An J, Zong L World J Gastrointest Oncol. 2024; 16(12):4548-4552.

PMID: 39678793 PMC: 11577357. DOI: 10.4251/wjgo.v16.i12.4548.

References
1.
Juang Y, Jeng Y, Chen C, Lien H . PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer. Mol Carcinog. 2016; 55(12):2247-2259. DOI: 10.1002/mc.22465. View

2.
Chiesa M, Colombo G, Piacentini L . DaMiRseq-an R/Bioconductor package for data mining of RNA-Seq data: normalization, feature selection and classification. Bioinformatics. 2017; 34(8):1416-1418. DOI: 10.1093/bioinformatics/btx795. View

3.
Diez M, Teule A, Salazar R . Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. Ann Gastroenterol. 2014; 26(1):29-36. PMC: 3959515. View

4.
Watts G, Futscher B, Holtan N, DeGeest K, Domann F, Rose S . DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 2008; 1:47. PMC: 2566571. DOI: 10.1186/1755-8794-1-47. View

5.
Chen Y, Xiao D, Zhang L, Cai C, Li B, Liu Y . The Role of in Cardiovascular Development and Function. Front Cell Dev Biol. 2021; 9:638542. PMC: 7876368. DOI: 10.3389/fcell.2021.638542. View